Beacon Biosignals is seeking to build an expansive brain wave dataset to boost the study of new drugs and diagnostics for neurological diseases, and it now has $86 million in fresh funding to help reach …
Metagenomi’s workforce cuts; Cogent’s $475M+ raise
Plus, stories about and Centessa Pharmaceuticals, Biohaven and Eledon Pharmaceuticals: 🛑 Metagenomi lays off a quarter of its workforce: CEO Brian Thomas has departed amid a
One Drop founder announces broad market CGM on Frontiers stage
One Drop founder Jeff Dachis brought his new product out of stealth mode at Frontiers Health — a CGM for use beyond Type 1 diabetes.
Alkermes breaks new ground in narcolepsy with orexin drug
Alkermes’ alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.
Here’s how the PD-(L)1xVEGF bispecific race is looking so far
The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape. For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving …
Bayer beats expectations with tougher times looming
Bayer’s third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead.
AI features in UK plan to reduce animal testing
The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.
Bayer’s pharma division makes some strides as restructuring continues
Bayer’s pharma unit is riding the wave of a strong year, buoyed by a new drug approval and market launch as well as growing sales for certain core medicines in the third quarter. CEO Bill …
Lundbeck, Otsuka back survey uncovering ‘blind spot’ around Alzheimer’s agitation
The survey, commissioned by the Alliance for Aging Research and sponsored by the two drugmakers, spanned 1,000 U.S. adults and 1,000 unpaid or family Alzheimer’s caregivers.
Ovid chief Jeremy Levin plans to step down, succeeded by COO
Ten years after founding Ovid Therapeutics, CEO Jeremy Levin plans to step down and hand over the top spot to COO Meg Alexander. Alexander will formally take the reins at the beginning of next year …
NHS braces for thousands of redundancies
UK Health Secretary Wes Streeting has given the green light to a series of NHS reforms that will see around 18,000 administrative roles abolished.
FDA appoints veteran Pazdur to replace Tidmarsh
The FDA has steadied the ship at CDER by naming veteran regulator Richard Pazdur as director, although he was reportedly reluctant to take the job.